Steward Partners Investment Advisory’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Steward Partners Investment Advisory’s Portfolio NGM Stock Details NGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-4,146	Closed	-$4.44K	–	3603
2023 Q3	$4.44K	Hold	4,146	–	–	﹤0.01%	2867
2023 Q2	$10.7K	Sell	4,146 -4,817	-54%	-$17.2K	﹤0.01%	2547
2023 Q1	$36.6K	Hold	8,963	–	–	﹤0.01%	1990
2022 Q4	$45K	Buy	8,963 +951	+12%	+$5.96K	﹤0.01%	1878
2022 Q3	$105K	Buy	8,012 +3,195	+66%	+$48.4K	﹤0.01%	1477
2022 Q2	$62K	Buy	4,817 +2,800	+139%	+$38.8K	﹤0.01%	1701
2022 Q1	$31K	Buy	+2,017	New	+$31.5K	﹤0.01%	2164
2021 Q4	–	Sell	-2,000	Closed	-$42K	–	3355
2021 Q3	$42K	Hold	2,000	–	–	﹤0.01%	1987
2021 Q2	$39K	Hold	2,000	–	–	﹤0.01%	3824
2021 Q1	$58.1K	Buy	+2,000	New	+$56K	﹤0.01%	1904

Other funds holding NGM

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Steward Partners Investment Advisory's NGM Position: Q4 2023 in Review

Steward Partners Investment Advisory sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q4 2023, closing a stake of 4,146 shares — an estimated $4.44K sold.

Steward Partners Investment Advisory first reported a position in NGM in Q1 2021 and held it in 10 quarters. The position peaked at $105K in Q3 2022. 83 funds tracked by Wall St. Rank hold NGM as of Q4 2023.

Steward Partners Investment Advisory reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Steward Partners Investment Advisory sold 4,146 NGM Biopharmaceuticals, Inc. Common Stock shares in Q4 2023, an estimated $4.44K.
Steward Partners Investment Advisory first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 10 quarters.
Steward Partners Investment Advisory's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $105K in Q3 2022.
83 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q4 2023.

Based on Steward Partners Investment Advisory's 13F filing for Q4 2023, filed 12 Feb 2024.